ADHD beyond core symptoms
Emotional dysregulation and functional impairment are as consequential as inattention and hyperactivity. How stimulants and atomoxetine compare across these dimensions determines which drug fits which patient.
Narrative Arc
Four framing steps for the review
01
ADHD Beyond Core Symptoms
Clinicians diagnose ADHD through inattention, impulsivity, and hyperactivity, but most patients carry a wider burden: volatile emotional reactions, difficulty recovering from affective triggers, and disrupted role performance.
02
Emotional Dysregulation and Functional Impairment in ADHD
Emotional dysregulation presents as mood instability, temper, and emotional overreactivity. Functional impairment shows up in academic performance, home life, friendships, work capacity, and quality of life. These dimensions, not symptom scores, usually decide whether patients consider their treatment worthwhile.
03
Rationale and Aims of the Review
The question is whether pharmacotherapy benefits extend beyond core symptom suppression, and whether stimulants and atomoxetine diverge on emotional and functional outcomes.
04
Pharmacologic Treatment of ADHD
The review centers on two major medication strategies: stimulants, which remain the dominant first-line option, and atomoxetine, a non-stimulant alternative with a distinct neurochemical profile and lower abuse potential.
Stimulants
Methylphenidate and amphetamines typically deliver strong effects on attention, behavioral control, and school-related functioning.
Atomoxetine
Atomoxetine shows durable emotional benefits in adults and in patients whose emotional profile drives treatment decisions.
Mechanism Comparison
Shared therapeutic goals, distinct pharmacologic routes
Methylphenidate & amphetamines
- Block DAT and NET to increase dopamine and norepinephrine in fronto-striatal circuits.
- Enhance salience processing and behavioral regulation through catecholaminergic modulation.
- Often associated with strong short-term gains in academic and functional performance in youth.
- Key adverse drug reactions include cardiovascular events, appetite suppression, insomnia, psychosis risk, and serotonin syndrome risk.
Selective norepinephrine reuptake inhibition
- Acts as a selective NET inhibitor, increasing norepinephrine and prefrontal dopamine.
- Does not raise striatal dopamine in the way stimulants do, supporting a low abuse-potential profile.
- Appears especially relevant for durable emotional improvement and emotion-linked treatment trajectories.
- Key adverse drug reactions include QT prolongation, a black box warning for suicidal ideation in children and adults, and rare hepatotoxicity.
Front: Mechanism
Stimulants
Methylphenidate and amphetamine formulations increase catecholamine signaling through DAT and NET blockade, amplifying dopamine and norepinephrine transmission across fronto-striatal networks tied to salience, control, and task engagement.
Back: Adverse Effects
Stimulants
Important safety considerations include cardiovascular events, appetite suppression, insomnia, psychosis risk, and serotonin syndrome risk, requiring careful patient-specific monitoring.
Front: Mechanism
Atomoxetine
Atomoxetine selectively inhibits NET, boosting norepinephrine and prefrontal dopamine without the same striatal dopamine signal, which helps explain its low abuse potential and distinct emotional response profile.
Back: Adverse Effects
Atomoxetine
Clinicians must weigh QT prolongation, the black box warning for suicidal ideation in children and adults, and rare hepatotoxicity when selecting atomoxetine.